CDP 571
Alternative Names: BAY 103356; BAY W 3356; CDP571; HumicadeLatest Information Update: 10 Sep 2003
At a glance
- Originator Celltech Group
- Developer Celltech Group; PDL BioPharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease; Rheumatoid arthritis; Septic shock; Type 2 diabetes mellitus
Most Recent Events
- 19 Aug 2003 Discontinued - Phase-II for Crohn's disease in Canada (IV)
- 19 Aug 2003 Discontinued - Phase-II for Crohn's disease in United Kingdom (IV)
- 19 Aug 2003 Discontinued - Phase-III for Crohn's disease in USA (IV-infusion)